GE Healthcare Technologies Inc. - 10-Q Summary (Q3 2025)
Business Context and Reporting Period
This filing covers the quarterly period ended September 30, 2025. GE Healthcare Technologies Inc. operates as a global healthcare solutions provider organized into four reportable segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). The company continues to navigate a complex macroeconomic environment characterized by global trade tariffs, geopolitical instability, and supply chain challenges.
Key Financial Metrics
| Metric (in millions) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Total Revenues | $5,143 | $4,863 | $14,927 | $14,353 |
| Operating Income | $653 | $676 | $1,936 | $1,824 |
| Net Income (Attributable to GEHC) | $446 | $470 | $1,495 | $1,272 |
| Diluted EPS | $0.98 | $1.02 | $3.26 | $2.77 |
| Operating Cash Flow (9M) | $937 | $1,042 | $937 | $1,042 |
| Free Cash Flow (9M) | $589 | $743 | $589 | $743 |
| Total Debt | $10,282 | $8,951 | $10,282 | $8,951 |
| Cash & Equivalents | $4,027 | $2,889 | $4,027 | $2,889 |
Note: Debt and Cash figures represent balances as of September 30, 2025, compared to December 31, 2024.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 6% in Q3 and 4% for the nine months ended September 30, 2025, compared to the prior year. Organic revenue growth was 4% for Q3 and 3% for the nine-month period.
- Segment Performance:
- PDx: Strongest performer with 20% revenue growth in Q3, driven by the acquisition of Nihon Medi-Physics (NMP) and organic volume/price increases.
- Imaging & AVS: Both segments showed growth (5% and 7% respectively in Q3), supported by strength in EMEA and USCAN regions.
- PCS: Declined 6% in Q3 due to a product hold and challenging comparisons in Life Support Solutions.
- Profitability Pressure: Operating income decreased 3% in Q3 despite revenue growth. Gross profit margins contracted due to cost inflation, incremental tariffs, and increased engineering costs for new product introductions.
- Acquisition Impact: The full acquisition of NMP in Q1 2025 resulted in a one-time gain of $97 million on the remeasurement of the previously held equity interest, significantly boosting net income for the nine-month period.
Guidance, Outlook, and Risks
- Outlook: Management expects tariffs to continue to materially impact profitability and cash flows. While mitigation actions are underway, the company does not expect to fully offset these additional costs.
- China Market: Revenue in China decreased 3% in Q3. Management notes that while the 2024 stimulus program offers long-term opportunities, short-term delays in provincial planning have slowed order intake.
- Geopolitical Risks: The company monitors the Russia-Ukraine conflict and Middle East tensions. Assets in Russia/Ukraine totaled $241 million, with revenues of $209 million for the nine months ended September 30, 2025. Export licenses are required for certain transactions.
- Capital Allocation: The company repurchased $200 million of common stock in the first nine months of 2025 under a $1 billion program. In Q2 2025, the company issued $1.5 billion in senior unsecured notes to refinance debt and fund operations.
- Legal Contingencies: A significant legal matter involving the Iraqi Ministry of Health remains pending before the D.C. Circuit Court of Appeals following a Supreme Court remand in June 2024.
Investor Verification Checklist
- Tariff Impact: Verify the specific magnitude of cost inflation attributed to new U.S. tariffs on global imports and the effectiveness of pricing strategies to pass these costs to customers.
- PCS Segment Turnaround: Monitor the resolution of the "product hold" in the Patient Care Solutions segment and the timeline for recovery in Life Support Solutions.
- China Stimulus Execution: Track the pace of provincial plan announcements in China to assess the duration of the revenue delay.
- Debt Refinancing: Confirm the successful repayment of the $1.5 billion senior notes due in November 2025, which was executed as a subsequent event on October 15, 2025.
- Non-GAAP Reconciliations: Review the reconciliation of Adjusted EBIT and Adjusted Net Income to understand the impact of the $97 million NMP remeasurement gain and restructuring costs on underlying operational performance.